A preliminary study investigating how a blood marker(betahydroxybutyrate) is affected by chemotherapy in breast cancer patients
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2024/06/069352
- Lead Sponsor
- DrNPKTeja Self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
All patients who have histopathologically confirmed breast malignancy and
Fit to receive Doxorubicin and Cyclophosphamide chemotherapy
Chemotherapy naive
Age above 18 years
Participants with
a.Haemoglobin above 8gm/dl,
b.Platelet count above 1,00,000/mm3
c.Absolute neutrophil count above 1500/ mm3
Patients with Left Ventricular Ejection Fraction more than 50%.
Participants with ECOG (Eastern Co-operative Oncology Group) performance status of 0-2.
Not willing to provide informed consent
Participants with history of, use of drugs causing bone marrow toxicity like, Lamotrigine, Dapsone, Quinidine,Quinine, Propylthiouracil, Clozapine, Vancomycin in the past 2 months.
Patients with Chronic Kidney Disease with Creatinine clearance lesser than 30ml/min
Patients with Chronic hepatic disorders with Serum total Bilirubin greater than 5mg/dl and Transaminases (ALT & AST more than 5 times normal limit
Patients with refractory anaemia and with history of blood transfusions
Patients with Uncontrolled Diabetes Mellitus with HbA1c greater than or equal to 8% .
Diabetic patients receiving Insulin.
Patients who are on keto diet.
Participants with history of alcohol intake in the past 7 days.
Patients with known hypersensitivity to Doxorubicin or Cyclophosphamide.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method